Outset Medical, Inc. (NASDAQ:OM) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Outset Medical, Inc. (NASDAQ:OM) have received a consensus rating of “Hold” from the five brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $10.00.

A number of equities research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research note on Friday, March 27th. TD Cowen reiterated a “buy” rating on shares of Outset Medical in a research report on Friday, May 8th. Finally, Wall Street Zen cut shares of Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th.

Insider Buying and Selling at Outset Medical

In other news, CFO Renee Gaeta sold 17,672 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $4.94, for a total value of $87,299.68. Following the completion of the transaction, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at approximately $561,939.82. This represents a 13.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 25,337 shares of company stock valued at $115,660. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Outset Medical

Institutional investors have recently bought and sold shares of the stock. BML Capital Management LLC lifted its holdings in Outset Medical by 250.2% during the 1st quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock valued at $7,304,000 after purchasing an additional 1,359,021 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Outset Medical by 165.8% in the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after acquiring an additional 262,874 shares in the last quarter. Ensign Peak Advisors Inc increased its holdings in Outset Medical by 71.8% during the 4th quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company’s stock valued at $2,078,000 after purchasing an additional 234,082 shares in the last quarter. Renaissance Technologies LLC raised its position in Outset Medical by 391.3% in the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock valued at $853,000 after purchasing an additional 176,870 shares during the last quarter. Finally, Alyeska Investment Group L.P. grew its holdings in shares of Outset Medical by 10.2% during the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after purchasing an additional 150,000 shares during the last quarter.

Outset Medical Trading Down 2.5%

Outset Medical stock opened at $4.76 on Wednesday. The business has a 50 day moving average price of $4.41 and a two-hundred day moving average price of $4.18. The company has a quick ratio of 4.97, a current ratio of 6.29 and a debt-to-equity ratio of 0.87. Outset Medical has a 12 month low of $3.00 and a 12 month high of $21.36. The stock has a market cap of $88.25 million, a price-to-earnings ratio of -1.14 and a beta of 1.95.

Outset Medical (NASDAQ:OM) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). The firm had revenue of $27.86 million for the quarter, compared to the consensus estimate of $28.90 million. Outset Medical had a negative net margin of 63.65% and a negative return on equity of 56.13%. As a group, equities analysts forecast that Outset Medical will post -3.82 EPS for the current year.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.